Neuropsychiatric symptoms and caregiver's burden in Parkinson's disease by Martinez-Martin, Pablo et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.parkreldis.2015.03.024
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Martinez-Martin, P., Rodriguez-Blazquez, C., Forjaz, M. J., Frades-Payo, B., Agüera-Ortiz, L., Weintraub, D., ...
Ray Chaudhuri, K. (2015). Neuropsychiatric symptoms and caregiver's burden in Parkinson's disease.
Parkinsonism & Related Disorders, 21(6), 629-634. 10.1016/j.parkreldis.2015.03.024
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 18. Feb. 2017
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.parkreldis.2015.03.024
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Martinez-Martin, P., Rodriguez-Blazquez, C., Forjaz, M. J., Frades-Payo, B., Agüera-Ortiz, L., Weintraub, D., ...
Ray Chaudhuri, K. (2015). Neuropsychiatric symptoms and caregiver's burden in Parkinson's disease: PD
neuropsychiatric symptoms and caregiver’s burden. Parkinsonism and Related Disorders, 21, 629-634. [21].
10.1016/j.parkreldis.2015.03.024
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 12. Jul. 2016
                             Elsevier Editorial System(tm) for Parkinsonism & Related Disorders 
                                  Manuscript Draft 
 
 
Manuscript Number:  
 
Title: Neuropsychiatric symptoms and caregiver's burden in Parkinson's disease 
 
Article Type: Full Length Article 
 
Keywords: Parkinson's disease, caregiver burden, neuropsychiatric symptoms 
 
Corresponding Author: Dr. Pablo Martinez-Martin, MD, PhD 
 
Corresponding Author's Institution: National Center of Epidemiology - ISCIII 
 
First Author: Pablo Martinez-Martin 
 
Order of Authors: Pablo Martinez-Martin; Carmen Rodriguez-Blazquez; Maria Joao Forjaz; Belen 
Frades-Payo; Luis Aguera-Ortiz; Daniel Weintraub; Ana Riesco; Monica M Kurtis; Kallol Ray Chaudhuri 
 
Abstract: Introduction: In Parkinson's disease (PD), neuropsychiatric symptoms (NPS) can be 
particularly burdensome for caregivers. The main goal of this study was to assess the impact of NPS, 
assessed by means of a new specific scale, on caregiver burden.Methods: A sample of 584 pairs of PD 
patients and their primary caregivers was studied. Patients' NPS were measured with the Scale for 
Evaluation of Neuropsychiatric Disorders in PD (SEND-PD), and the Zarit Caregiver Burden Inventory 
was used to quantify caregiver burden. Three linear regression models were built to check factors 
associated with caregiver burden, one for the total sample and two for subgroups stratified by the 
presence of dementia. Results: The most prevalent SEND-PD dimensions were mood/apathy (87.4%), 
followed by psychotic symptoms (48.5%) and impulse control disorders (26.5%). Patients with 
dementia (n=94; 16.15% of sample) consistently presented more NPS than patients without dementia 
(p<0.001). On linear regression models, the main determinants of caregiver burden (for the total 
sample and the sample of patients without dementia) were SEND-PD dimensions mood/apathy and 
psychosis, PD-related disability and disease duration. For patients with dementia, the only significant 
caregiver burden determinants were SEND-PD psychosis and mood/apathy subscale 
scores.Conclusions: NPS in PD are highly associated with and are determinants of caregiver burden, 
and are more prevalent and burdensome in patients with dementia. Detailed assessment and specific 
interventions aimed at NPS could alleviate caregiver burden. 
 
 
 
 
Author Declaration 
 
Parkinsonism & Related Disorders is committed to proper scientific conduct and 
the protection of animal and human research subjects. Submission of this 
manuscript implies compliance with the following ethical requirements. Please 
affirm that you are representing all of the authors in stating compliance with these 
policies by checking the box at the end of this section.  
 
1. Studies with human subjects must have been conducted in accordance with the 
Declaration of Helsinki. All persons must have provided informed consent prior to 
being included in the study.   
 
2. Studies with animal subjects must have been conducted in accordance with the 
Guide for the Care and Use of Laboratory Subjects as adopted by the US National 
Institutes of Health and/or according to the requirements of all applicable local, 
national and international standards. 
 
3.  Protocols with animal or human subjects must have been approved by the 
relevant local committee(s) charged with ensuring subject protection. Studies that 
entail pain or distress will be assessed in terms of the balance between the distress 
inflicted and the likelihood of benefit. 
 
4. The authors declare that the manuscript is original, that it is not being 
considered for publication elsewhere, and that it will not be submitted elsewhere 
while still under consideration for Parkinsonism & Related Disorders or after it 
has been accepted by Parkinsonism & Related Disorders. 
 
5. All authors have seen and approved the manuscript in the form submitted to the 
journal. The authors declare that they have conformed to the highest standards of 
ethical conduct in the submission of accurate data and that they acknowledge the 
work of others when applicable. 
 
6. All sources of financial support for the work have been declared in the 
Acknowledgements section of the manuscript. Any additional conflicts of interest 
must also be declared. Please include declarations of any consultancy or research 
funding received from relevant companies from three years prior to performance 
of the research until the time of manuscript submission. If the research is 
supported by internal funds, that should be stated as well. 
 
 
To indicate compliance with the preceding declaration and that you have obtained 
agreement from all of the authors of this paper to declare their compliance as well, 
please place an x here: _X__ 
 
In cases of uncertainty please contact an editor for advice. 
 
Author Declaration
Prof. Pfeiffer and Prof. Wszolek 
Editors-in-Chief 
Parkinsonism and Related Disorders 
 
 
November 6th, 2014 
Dear Professors, 
 
Please, find attached our manuscript “Neuropsychiatric symptoms and caregiver’s 
burden in Parkinson’s disease” to be considered for publication as a full length article in 
the prestigious journal that you head. 
 
As first and corresponding author, I declare that all authors expressed their conformity 
with the current version, this is an original paper that has not been published previously, 
and it is not in consideration by any other journal. 
 
Yours sincerely, 
 
Dr Pablo Martinez-Martin 
On behalf of all co-authors 
*Cover Letter
Highlights 
 
 In Parkinson’s disease (PD), neuropsychiatric symptoms (NPS) notably increase 
caregiver burden 
 In this study, NPS were assessed with the Scale for Evaluation of 
Neuropsychiatric Disorders in PD  
 PD patients with dementia experience more NPS, a fact adding extra burden to 
caregivers 
 NPS were the main determinant of caregiver burden, both in PD patients with 
and without dementia 
 
*Highlights (for review)
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
1 
 
 
Neuropsychiatric symptoms and caregiver’s burden in Parkinson’s disease 
 
Pablo Martinez-Martin1, Carmen Rodriguez-Blazquez1, Maria João Forjaz2, Belén 
Frades-Payo3, Luis Agüera-Ortiz3,4, Daniel Weintraub5, Ana Riesco3, Monica M. 
Kurtis6, Kallol Ray Chaudhuri7 
 
1. National Center of Epidemiology and CIBERNED, Carlos III Institute of Health. 
Madrid, Spain 
2. National School of Public Health and REDISSEC, Carlos III Institute of Health. 
Madrid, Spain 
3. Research Unit, Alzheimer Center Reina Sofia Foundation, Carlos III Institute of 
Health. Madrid, Spain 
4. CIBERSAM, Carlos III Institute of Health. Madrid, Spain 
5. Departments of Psychiatry and Neurology, Perelman School of Medicine at the 
University of Pennsylvania, Philadelphia, USA; Philadelphia Veterans Affairs Medical 
Center, Philadelphia, USA 
6. Department of Neurology, Hospital Ruber Internacional. Madrid, Spain 
7. National Parkinson Foundation Centre of Excellence, Department of Neurology, 
King’s College Hospital, and Kings Health Partners, London, UK2 
 
Corresponding author: 
Pablo Martínez-Martín 
National Centre of Epidemiology 
Av. Monforte de Lemos, 3 
28029 Madrid, Spain 
pmartinez@isciii.es 
 
Word count: 2381 
Running title: PD neuropsychiatric symptoms and caregiver’s burden 
Disclosure: Authors declare no conflict of interest. 
*Manuscript
Click here to view linked References
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
2 
 
Abstract 
Introduction: In Parkinson’s disease (PD), neuropsychiatric symptoms (NPS) can be 
particularly burdensome for caregivers. The main goal of this study was to assess the 
impact of NPS, assessed by means of a new specific scale, on caregiver burden. 
Methods: A sample of 584 pairs of PD patients and their primary caregivers was 
studied. Patients’ NPS were measured with the Scale for Evaluation of Neuropsychiatric 
Disorders in PD (SEND-PD), and the Zarit Caregiver Burden Inventory was used to 
quantify caregiver burden. Three linear regression models were built to check factors 
associated with caregiver burden, one for the total sample and two for subgroups 
stratified by the presence of dementia.  
Results: The most prevalent SEND-PD dimensions were mood/apathy (87.4%), 
followed by psychotic symptoms (48.5%) and impulse control disorders (26.5%). 
Patients with dementia (n=94; 16.15% of sample) consistently presented more NPS than 
patients without dementia (p<0.001). On linear regression models, the main 
determinants of caregiver burden (for the total sample and the sample of patients 
without dementia) were SEND-PD dimensions mood/apathy and psychosis, PD-related 
disability and disease duration. For patients with dementia, the only significant 
caregiver burden determinants were SEND-PD psychosis and mood/apathy subscale 
scores. 
Conclusions: NPS in PD are highly associated with and are determinants of caregiver 
burden, and are more prevalent and burdensome in patients with dementia. Detailed 
assessment and specific interventions aimed at NPS could alleviate caregiver burden. 
Keywords: Parkinson’s disease, caregiver burden, neuropsychiatric symptoms 
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Highlights 
 
• In Parkinson’s disease (PD), neuropsychiatric symptoms (NPS) notably increase 
caregiver burden 
• In this study, NPS were assessed with the Scale for Evaluation of 
Neuropsychiatric Disorders in PD  
• PD patients with dementia experience more NPS, a fact adding extra burden to 
caregivers 
• NPS were the main determinant of caregiver burden, both in PD patients with 
and without dementia 
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INTRODUCTION  
Parkinson’s disease (PD) is a chronic, neurodegenerative condition that 
significantly impacts on patients and on those who look after them on a daily basis. As 
their health status deteriorates, patients need progressively more assistance to perform 
their activities of daily living. Caregiving is time consuming and demanding. Its 
negative impact on the caregiver’s health, social life and financial situation is 
summarized in the construct of “caregiver burden” [1].  
Factors influencing caregiver burden are related to caregiver and patient 
characteristics, including PD manifestations and consequences [2]. Patients differ 
substantially on their degree of disability, motor and non-motor symptom profiles, and 
complications of therapy [3], all of which may have a differential impact on caregiver 
burden. Neuropsychiatric symptoms (NPS), such as anxiety, depression, apathy, mental 
fatigue, psychosis, and impulse control disorders (ICDs) are highly prevalent, affecting 
up to 60-80% of patients with PD [4]. Although NPS can occur in PD patients without 
dementia [5], cognitive impairment is a correlate of most of these disturbances and, as a 
whole, NPS are more frequent in patients with dementia. Their co-occurrence highly 
increases caregivers burden [6–8]. Both, presence and severity of NPS are associated 
with increased caregiver burden [6,9] and, by modality, psychotic symptoms are 
especially important. They are disruptive, significantly increase caregiver burden [6,9] 
and can lead to institutionalization of PD patients [10,11].  
The present study aims to assess how NPS, measured with the disease-specific 
Scale for Evaluation of Neuropsychiatric Disorders in PD (SEND-PD) [12], impact on 
caregiver burden. We hypothesized that: 1) There is a significant relationship between 
caregiver burden and NPS; 2) PD patients with dementia present more NPS than PD 
patients without dementia; 3) Caregivers will suffer more burden when patients 
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experience NPS with dementia; 4) NPS are the main determinants of caregiver burden 
both in PD patients with and without dementia. 
 
METHODS 
Sample 
The sample consisted of 584 pairs of consecutive patients and their main 
caregivers from the SEND-PD validation study [12]. Patients were included if: PD 
diagnosis was made by a neurologist according to internationally recognized diagnostic 
criteria [13]; caregiver was present during the visit; and patients or their legal 
representative signed informed consent. Patients who did not meet all inclusion criteria 
or who had a condition that could hamper the assessment were excluded. 
The caregiver was defined as “any person who, without being a professional or 
belonging to a social support network, usually lives with the patient and, in some way, 
is directly implicated in the patient’s care or is directly affected by the patient’s health 
problem” [2]. Caregiver inclusion criteria were: age 18 years or older, ability to 
complete self-administered questionnaires in Spanish, and willingness to sign informed 
consent. 
 
Ethical Approval 
The study was approved by the institutional review boards of the Carlos III 
Institute of Health and Alzheimer’s Disease Research Unit, CIEN Foundation and was 
reported to the Spanish Medicines Agency [12]. Patients or their legal representative 
signed informed consent. 
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Assessments 
The following evaluations were carried out: Hoehn & Yahr staging (HY) [14] 
and Clinical Impression of Severity Index for PD (CISI-PD) [15]; Scales for Outcomes 
in PD-Motor (SCOPA-Motor) [16]; Mini-Mental State Examination (MMSE) [17], and 
the Pill Questionnaire and Lexical Fluency, according to the diagnostic procedures for 
PD dementia [18]. The Scale for Evaluation of Neuropsychiatric Disorders in PD 
(SEND-PD) was used to assess the presence of NPS [12].  
A clinical judgment on the dementia status of each patient (normal, cognitive 
impairment without dementia, or dementia and degree of severity), based on the 
patient’s medical record, interview with the patient and caregiver, and assessments, was 
recorded. This question was used to group patients with or without dementia. 
The SEND-PD is a rater-based scale specifically developed to assess the severity 
of most relevant NPS found in PD. It is informed by the patients or caregivers if patients 
can not answer the questions properly. Its 12 items are grouped in three dimensions: 
psychotic symptoms (4 items), mood/apathy (5), and ICD and related behaviors (3). 
Items are scored from 0 (not present) to 4 (very severe) and a total sum score is obtained 
for each domain. It shows satisfactory psychometric properties [12]. 
 Caregiver burden was assessed with the Zarit Caregiver Burden Inventory 
(ZCBI) [19], a 22-item measure assessing the impact of the patient’s disease or 
disability on the caregiver’s physical, emotional, social and financial situation. Items are 
scored from 0 (never) to 4 (nearly always), with a maximum total score of 88 indicating 
the highest level of caregiver burden.  
Socio-demographic data from patients and caregivers were collected. Levodopa 
equivalent daily doses (LEDD) were calculated [20]. 
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Data analysis 
Descriptive statistics were used for socio-demographic and clinical variables. 
For NPS prevalence, the percentage of patients scoring >0 (presence of the symptom) in 
each SEND-PD item and domain was calculated for the total sample and by dementia 
status (patients with and without dementia). 
To analyze the relationship between ZCBI and the other variables, Spearman’s 
correlation coefficients were determined for the total sample and dementia status 
groups. Coefficients of 0.35-0.59 were deemed as moderate, while coefficients ≥0.60 
were considered high [21].  
ZCBI mean values were calculated in the sample broken down by groups of 
interest: patients’ and caregivers’ sex and age, education level, relationship, disease 
duration, HY, cognitive status, and presence of NPS as per SEND-PD subscales. Mann-
Whitney and Kruskal-Wallis tests were used to ascertain the differences between 
groups. In addition, specific comparisons of caregiver burden were determined for 
patients with NPS according to their dementia status (Mann-Whitney tests). 
A linear regression model was built using ZCBI as the dependent variable and 
disease duration, disability, NPS and dementia status as independent variables. Similar 
models, removing dementia status as predictor, were then repeated for the groups by 
dementia status. Linear regression assumptions were previously checked.  
 
RESULTS  
Table 1 presents patients and caregivers description. Table 2 displays the 
prevalence of NPS assessed by the SEND-PD. The SEND-PD was responded by 
patients (87.03%), caregivers (12.59%) or both (0.38%). 
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Patients with dementia (n=94; 16.15%) consistently presented more NPS than 
patients without dementia (p<0.007) in all domains (Table 2). For patients with 
dementia, the most prevalent symptom was apathy. For patients without dementia, the 
most prevalent symptom was depression. For the entire sample, the most prevalent 
symptoms were depression and anxiety 
ZCBI score in total sample was moderately associated with CISI-PD (rS=0.56, 
p<0.001), SCOPA-Motor (rS=0.56, p<0.001), and PIGD scores (rS=0.53, p<0.001). A 
moderate association was also observed with HY stage (rS=0.46, p<0.001) and MMSE 
(rS=-0.35, p<0.001). ZCBI score correlated 0.32 to 0.53 with the SEND-PD dimensions 
(p<0.001) in the total sample. In the group without dementia, ZCBI correlated 0.34 with 
SEND-PD Psychotic, 0.44 with Mood/Apathy and 0.25 with Impulse Control Disorders 
(p<0.001), while in the group with dementia, correlation coefficients with SEND-PD 
subscales were 0.51, 0.34, and 0.32, respectively (p<0.001). 
Caregivers of patients with NPS reported significantly higher burden than 
caregivers of patients without symptoms (p<0.001; Table 3). Comparing the group of 
patients with NPS by dementia status, caregivers of patients with dementia reported a 
significantly higher burden than those without dementia (p<0.001 for the three SEND-
PD subscales; Table 3). 
Linear regression models (Table 4) indicate that the SEND-PD dimensions 
mood/apathy (standardized β=0.28) and psychosis (β= 0.18); disability (β=0.21) and 
disease duration (β=0.11) were significant determinants of ZCBI score for the entire 
cohort.  
Caregiver burden of patients without dementia was associated with higher 
SEND-PD mood/apathy (β=0.28) and psychosis scores (β=0.15), higher disability 
(β=0.21) and longer disease duration (β=0.13). For patients with dementia, the only 
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significant determinants were SEND-PD psychosis (β=0.31) and mood/apathy scores 
(β= 0.28).  
 
DISCUSSION 
In PD, motor symptoms and complications are well established factors that are 
intrusive to daily life and increase caregiver burden. The aim of this study was to assess 
the impact of NPS and dementia on caregivers’ burden, using a recently developed PD-
specific scale for the assessment of NPS, the SEND-PD [12]. 
In our cohort, caregivers were mostly middle-aged women who took care of a 
male patient/spouse, a profile coincident with most studies on PD caregivers [5,22]. In 
the present study, ZCBI scores were associated with SEND-PD dimensions, thus 
confirming the first hypothesis on a relationship between caregiver burden and presence 
and severity of NPS. Also, and in agreement with a previous study [5], other PD aspects 
such as motor impairment, disease severity and PD subtype, were also related to 
caregiver burden. Interestingly, the correlation between caregivers’ burden and 
psychotic symptoms was higher in PD patients with dementia than in those with normal 
cognition. PD patients with dementia have a greater prevalence of psychotic symptoms 
than patients without dementia, as hypothesized in this study, and this fact increases 
caregiver burden [23,24].  
Different profiles of NPS according to cognitive status were observed in this 
study: while PD patients with normal cognitive function had more depression and 
anxiety, PD patients with dementia showed higher percentages of apathy/lack of 
initiative and mental fatigue. For the entire sample, the most prevalent NPS were those 
pertaining to the mood/apathy domain, followed by psychotic symptoms. These results 
are in line with previous studies [4,8] and highlight the need for carrying out complete 
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neuropsychiatric assessments of PD patients in clinical practice, and for evaluating the 
effects that PD treatments may have on NPS [8]. 
Caregivers reported significantly more burden when patients experienced NPS 
and dementia, suggesting a synergetic effect of dementia and NPS on caregiver burden. 
This confirms our third hypothesis and is congruent with previously reported increased 
caregiver burden in patients with dementia, compared with those without dementia [23].  
Our study identified mood/apathy and psychosis as significant determinants of 
caregiver burden. Disability and disease duration also contributed significantly to 
caregiver burden in patients without dementia. ICD symptoms were not associated with 
caregiver burden when controlling for other factors. This confirms our fourth hypothesis 
that NPS are main determinants of caregiver burden, particularly mood/apathy and 
psychosis, while ICDs may play a lesser role. This is consistent with a recent study 
reporting that although caregivers of patients with ICD displayed more burden than 
caregivers of patients without ICD, the association between ICD symptoms and 
caregiver burden was low [25]. In another study, cognitive behavioral therapy for 
patient’s ICD did not alleviate caregiver burden [26]. 
Previous studies have documented the significant impact of the patient’s 
mood/apathy [25], psychotic symptoms [4], disability [9,22] and disease duration [27] 
on caregiver burden [28]. Screening for these factors, and specifically patient’s NPS and 
dementia, may help identify caregivers who could benefit from intervention strategies 
such as group support or respite care [29].  
According to the stress-appraisal model of caregiver wellbeing, behavioral 
problems (including NPS), cognitive impairment (dementia in our study) and functional 
dependency are primary stressors that have a direct impact on caregiver burden, as well 
as an indirect effect through mediator variables [30,31]. Our results indicate that the 
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contribution of NPS and disability to caregiver burden is different for patients with and 
without dementia. In the group of patients with dementia, the only significant 
determinants of caregiver burden were mood/apathy and psychotic symptoms. Further 
studies are needed to investigate if dementia could also be acting in moderating the 
relationship between primary stressors and caregiver burden. 
Our study has some limitations, such as the convenience sample used. However, 
its relatively large size and patients characteristics similar to other studies allow 
confidence in the consistency of the reported results. Furthermore, the cross-sectional 
design prevents from making causal inferences. Information from patients in more 
advanced stages or with dementia was obtained through their caregivers, which may 
bias the data. Finally, further studies are needed that explore more deeply what 
characteristics of caregivers might influence its burden. 
In conclusion, caregivers of patients with PD are subjected to a variety of 
problems that influence their health, social life, financial situation, and quality of life. 
What this study adds is the use of a new specific instrument for assessment of NPS 
(SEND-PD), which enabled us to confirm that these disorders were closely associated 
with caregiver burden, were more prevalent and burdensome in patients with dementia, 
and performed as the main determinants of the caregiver burden in this study.  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
12 
 
Financial Disclosures 
Pablo Martinez-Martin received honoraria from speaking engagements at scientific 
meetings of Abbvie and Teva, and from serving in a scientific advisory board of 
Abbvie; grants from Carlos III Institute of Health, IMSERSO, Reina Sofia Foundation, 
and Michael J. Fox Foundation. He is Chair of the IPMDS Committee for Development 
of Rating Scales. His employment is at Carlos III Institute of Health. 
Carmen Rodríguez-Blázquez has nothing to disclose. Her employment is at Carlos III 
Institute of Health. 
Maria João Forjaz has nothing to disclose. Her employment is at Carlos III 
Institute of Health. 
Belén Frades-Payo has nothing to disclose. Her employment is at Alzheimer Center 
Reina Sofia Foundation, Carlos III Institute of Health. 
Luis Agüera-Ortiz has nothing to disclose. His employment is at Alzheimer Center 
Reina Sofia Foundation, Carlos III Institute of Health. 
Daniel Weintraub has received research funding from Michael J. Fox Foundation for 
Parkinson’s Research, National Institutes of Health, Novartis Pharmaceuticals, 
Department of Veterans Affairs, and Alzheimer’s Disease Cooperative Study; honoraria 
from Biotie, Teva Pharmaceuticals, Lundbeck Inc., Pfizer, Avanir Pharmaceuticals, 
Acadia Pharmaceuticals, Merck & Co., UCB, Bristol-Myers Squibb Company, Novartis 
Pharmaceuticals, Clintrex LLC, Theravance, Medivation, CHDI Foundation, and the 
Weston Foundation; license fee payments from the University of Pennsylvania for the 
QUIP and QUIP-RS; and fees for testifying in two court cases related to impulse 
controls disorders in Parkinson’s disease (March, 2013-April, 2014, payments by 
Eversheds and Roach, Brown, McCarthy & Gruber, P.C.). He is Associate Professor of 
Psychiatry and Neurology at Perelman School of Medicine (University of 
Pennsylvania). 
Ana Riesco has nothing to disclose.  
Monica M. Kurtis received personal fees from UCB Pharma for lectures. She is 
employed at Hospital Ruber Internacional. 
Kallol Ray Chaudhuri has received funding from Parkinson’s UK, NIHR, UCB, 
European Union and has received honorarium from UCB, Abbott, Britannia, US 
Worldmeds, Otsuka pharmaceuticals in the last 3 years and acted as a consultant for 
Abbvie, UCB, Britannia. His employment is at King’s College Hospital.  
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
13 
 
Authors’ Roles 
1 – Conception and Design: Pablo Martinez-Martin. Acquisition of data: Belén Frades-
Payo, Luis Agüera-Ortiz. Analysis of data: Pablo Martinez-Martin, Carmen Rodriguez-
Blazquez, Maria João Forjaz, Ana Riesco. Interpretation of data: Pablo Martinez-
Martin, Carmen Rodriguez-Blazquez, Maria João Forjaz. 
2 – Drafting of the manuscript: Pablo Martinez-Martin, Carmen Rodriguez-Blazquez, 
Maria João Forjaz. Critical review of the draft: All the coauthors. 
3 – Final approval of the submitted manuscript: All the coauthors. 
 
Acknowledgments 
The authors acknowledge UCB Pharma Spain, Pivotal S.L., and The SEND-PD Group 
for their help in the validation study. This study was not funded.  
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
14 
 
REFERENCES 
1.  McRae C, Sherry P, Roper K. Stress and family functioning among caregivers of 
persons with Parkinson’s disease. Parkinsonism Relat Disord. 1999;5(1-2):69–75.  
2.  Martínez-Martín P, Forjaz MJ, Frades-Payo B, Rusiñol AB, Fernández-García 
JM, Benito-León J, et al. Caregiver burden in Parkinson’s disease. Mov Disord. 
2007;22(7):924–31.  
3.  Thenganatt MA, Jankovic J. Parkinson disease subtypes. JAMA Neurol. 
2014;71(4):499–504.  
4.  Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson’s 
disease. Mov Disord. 2009;24(15):2175–86.  
5.  Lee AH, Weintraub D. Psychosis in Parkinson’s disease without dementia: 
common and comorbid with other non-motor symptoms. Mov Disord. 
2012;27(7):858–63.  
6.  Stella F, Banzato CEM, Quagliato EMAB, Viana MA, Christofoletti G. 
Psychopathological features in patients with Parkinson’s disease and related 
caregivers’ burden. International Journal of Geriatric Psychiatry. 
2009;24(10):1158–65.  
7.  Forsaa EB, Larsen JP, Wentzel-Larsen T, Goetz CG, Stebbins GT, Aarsland D, et 
al. A 12-year population-based study of psychosis in Parkinson disease. Arch 
Neurol. 2010;67(8):996–1001.  
8.  Weintraub D, Burn DJ. Parkinson’s disease: the quintessential neuropsychiatric 
disorder. Mov Disord. 2011;26(6):1022–31.  
9.  Schrag A, Hovris A, Morley D, Quinn N, Jahanshahi M. Caregiver-burden in 
parkinson’s disease is closely associated with psychiatric symptoms, falls, and 
disability. Parkinsonism Relat Disord. 2006;12(1):35–41.  
10.  Factor SA, Feustel PJ, Friedman JH, Comella CL, Goetz CG, Kurlan R, et al. 
Longitudinal outcome of Parkinson’s disease patients with psychosis. Neurology. 
2003;60(11):1756–61.  
11.  Kang GA, Bronstein JM. Psychosis in nursing home patients with Parkinson’s 
disease. J Am Med Dir Assoc. 2004;5(3):167–73.  
12.  Martinez-Martin P, Frades-Payo B, Agüera-Ortiz L, Ayuga-Martinez A. A short 
scale for evaluation of neuropsychiatric disorders in Parkinson’s disease: first 
psychometric approach. J Neurol. 2012;259(11):2299–308.  
13.  Lees AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet. 2009;373(9680):2055–
66.  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
15 
 
14.  Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. 
Neurology. 1967;17(5):427–42.  
15.  Martínez-Martín P, Forjaz MJ, Cubo E, Frades B, de Pedro Cuesta J. Global 
versus factor-related impression of severity in Parkinson’s disease: A new 
clinimetric index (CISI-PD). Movement Disorders. 2006;21(2):208–14.  
16.  Marinus J, Visser M, Stiggelbout AM, Rabey JM, Martínez-Martín P, Bonuccelli 
U, et al. A short scale for the assessment of motor impairments and disabilities in 
Parkinson’s disease: the SPES/SCOPA. J Neurol Neurosurg Psychiatr. 
2004;75(3):388–95.  
17.  Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method 
for grading the cognitive state of patients for the clinician. J PsychiatrRes. 
1975;12(3):189–98.  
18.  Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA, et al. Diagnostic 
procedures for Parkinson’s disease dementia: recommendations from the 
movement disorder society task force. Mov Disord. 2007;22(16):2314–24.  
19.  Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: 
correlates of feelings of burden. Gerontologist. 1980;20(6):649–55.  
20.  Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review 
of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord. 
2010;25(15):2649–53.  
21.  Fisk JD, Brown MG, Sketris IS, Metz LM, Murray TJ, Stadnyk KJ. A comparison 
of health utility measures for the evaluation of multiple sclerosis treatments. J 
NeurolNeurosurgPsychiatry. 2005;76(1):58–63.  
22.  Drutyte G, Forjaz MJ, Rodriguez-Blazquez C, Martinez-Martin P, Breen KC. 
What impacts on the stress symptoms of Parkinson’s carers? Results from the 
Parkinson’s UK Members’ Survey. Disabil Rehabil. 2014;36(3):199–204.  
23.  Leroi I, McDonald K, Pantula H, Harbishettar V. Cognitive impairment in 
Parkinson disease: impact on quality of life, disability, and caregiver burden. J 
Geriatr Psychiatry Neurol. 2012;25(4):208–14.  
24.  Martinez-Martin P, Falup-Pecurariu C, Rodriguez-Blazquez C, Serrano-Dueñas 
M, Carod Artal FJ, Rojo Abuin JM, et al. Dementia associated with Parkinson’s 
disease: applying the Movement Disorder Society Task Force criteria. 
Parkinsonism Relat Disord. 2011;17(8):621–4.  
25.  Leroi I, Harbishettar V, Andrews M, McDonald K, Byrne EJ, Burns A. Carer 
burden in apathy and impulse control disorders in Parkinson’s disease. Int J 
Geriatr Psychiatry. 2012;27(2):160–6.  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
16 
 
26.  Okai D, Askey-Jones S, Samuel M, O’Sullivan SS, Chaudhuri KR, Martin A, et 
al. Trial of CBT for impulse control behaviors affecting Parkinson patients and 
their caregivers. Neurology. 2013;80(9):792–9.  
27.  Viwattanakulvanid P, Kaewwilai L, Jitkritsadakul O, Brenden NR, 
Setthawatcharawanich S, Boonrod N, et al. The impact of the nocturnal 
disabilities of Parkinson’s disease on caregivers’ burden: implications for 
interventions. J Neural Transm. 2014;  
28.  Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ. Quality of life and burden 
in caregivers for patients with Parkinson’s disease: concepts, assessment and 
related factors. Expert Rev Pharmacoecon Outcomes Res. 2012;12(2):221–30.  
29.  Tew EH, Naismith SL, Pereira M, Lewis SJG. Quality of life in Parkinson’s 
disease caregivers: the contribution of personality traits. Biomed Res Int. 
2013;2013:151872.  
30.  Goldsworthy B, Knowles S. Caregiving for Parkinson’s disease patients: an 
exploration of a stress-appraisal model for quality of life and burden. J Gerontol B 
Psychol Sci Soc Sci. 2008;63(6):372–6.  
31.  Chappell NL, Reid RC. Burden and well-being among caregivers: examining the 
distinction. Gerontologist. 2002;42(6):772–80.  
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
17 
 
Table 1. Sociodemographic and clinical variables of patients and caregivers 
Table 2. Prevalence of neuropsychiatric symptoms (SEND-PD) for patients with and 
without dementia 
Table 3. Zarit values in the sample broken down by groups of interest. 
Table 4. Linear regression models for Zarit as dependent variable. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
18 
 
Table 1. Sociodemographic and clinical variables of patients and caregivers 
 
Patients 
Variable   n %  Variable M SD 
Sex Men 336 58.43  Age 70.75 9.85 
 Women 239 41.57  Age at PD onset 62.76 10.41 
Education None 89 15.37  PD duration 8.07 5.57 
 Primary 301 51.99  LEDD  201.87 136.71 
 High school 124 21.42  DA-Agonist LEDD 683.15 426.49 
 University 65 11.23  SCOPA-MEx 12.48 6.95 
Work Retired 355 61.5  SCOPA-ADL 6.77 4.52 
 Housewives 107 18.5  SCOPA-MComp 2.31 2.64 
 Employed 33 5.7  SCOPA-Motor total 21.55 12.80 
 Other 82 14.3  MMSE 26.01 4.44 
HY 1 133 22.81  CISI-PD 8.65 4.91 
 2 268 45.97  SEND-PD:   
 3 104 17.84  - Psychotic  1.33 2.23 
 4 62 10.63  - Mood/apathy 4.49 3.64 
 5 16 2.74  - ICD 0.57 1.30 
Caregivers 
Variable   n %  Variable M SD 
Sex Men 166 29.54  Age 59.62 13.97 
 Women 396 70.46  Zarit 21.87 16.59 
Relationship Spouse 349 61.23     
 Children 168 29.47     
 Other 53 9.3     
N: number; M: mean; SD: standard deviation; HY: Hoehn & Yahr Staging; PD: Parkinson’s 
disease; LEDD: levodopa equivalent daily dose; DA-Agonist: Dopamine-agonist. SCOPA: 
Scales for Outcomes in Parkinson’s Disease; MEx: Motor exploration; ADL: Activities of daily 
living; MComp: Motor complications; MMSE: Mini-mental Status Examination; CISI-PD: 
Clinical Impression of Severity Index for Parkinson’s Disease; SEND-PD: Scale for Evaluation 
of Neuropsychiatric Disorders in Parkinson’s Disease; ICD: Impulse control disorders. 
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Table 2. Prevalence of neuropsychiatric symptoms (SEND-PD) for patients with 
and without dementia 
 
 Prevalence* 
 Total 
PD-No 
dementia 
(n=488) 
PD 
Dementia 
(n=94) 
p** 
1. Irritability/Aggressiveness 38.4 33.4 63.8 <0.001 
2. Delusions 17.6 11.1 51.1 <0.001 
3. Misidentification 20.7 12.3 63.8 <0.001 
4. Hallucinations 22.8 15.8 58.5 <0.001 
SEND-PD Psychotic symptoms 48.5 41.6 84.0 <0.001 
5. Social/Verbal withdrawn 55.3 49.8 83.0 <0.001 
6. Apathy/Lack initiative 54.8 48.0 90.4 <0.001 
7. Mental fatigue 57.5 51.4 89.4 <0.001 
8. Depression 65.6 63.1 77.7 0.007 
9. Anxiety 64.7 62.1 77.7 0.004 
SEND-PD Mood/Apathy 87.3 85.7 95.7 0.007 
10. Hobbyism/punding 18.3 13.9 40.4 <0.001 
11. Poor impulse control 18.2 15.2 33.0 <0.001 
12. Abuse of medication 6.9 4.9 16.0 <0.001 
SEND-PD Impulse control disorders 26.5 22.5 46.8 <0.001 
Patients with NPS 89.6 87.9 97.9 <0.001 
* Percentage of patients with SEND-PD Positive answer 
** Chi-squared 
PD: Parkinson’s disease; SEND-PD: Scale for Evaluation of Neuropsychiatric Disorders in 
Parkinson’s Disease; NPS: neuropsychiatric symptoms. 
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Table 3. Zarit values in the sample broken down by groups of interest. 
 
Variable Levels N* Mean SD p 
Total sample      
SEND-PD Psychotic 
No (0) 298 15.45 12.09 
<0.001 (MW) 
Yes (≥1) 274 28.86 17.96 
SEND-PD Mood/Apathy 
No (0) 74 10.09 9.63 
<0.001 (MW) 
Yes (≥1) 498 23.62 16.70 
SEND-PD IC disorders 
No (0) 421 18.89 15.18 
<0.001 (MW) 
Yes (≥1) 151 30.19 17.56 
PD Dementiaa 
No 477 19.21 14.93 
<0.001 (MW) 
Yes 93 35.82 17.78 
Dementia severity  
No dementia  477 19.21 14.93 
<0.001 (KW) Mild 46 30.93 17.77 
Moderate 37 37.86 16.07 
Severe  10 50.70 15.33 
Patients with NPS Levels N Mean SD p 
SEND-PD Psychotic  No PD-Dementia 195 24.80 16.713 <0.001 (MW) 
 PD-Dementia 78 39.38 16.595  
SEND-PD Mood/Apathy No PD-Dementia 407 20.75 15.126 <0.001 (MW) 
 PD-Dementia 89 37.12 17.034  
SEND-PD IC disorders No PD-Dementia 106 25.89 16.711 <0.001 (MW) 
 PD-Dementia 44 41.25 14.205  
SD: standard deviation; SEND-PD: Scale for Evaluation of Neuropsychiatric Disorders in 
Parkinson’s Disease; NPS: neuropsychiatric symptoms; PD-Dementia: Parkinson’s disease with 
dementia; MW: Mann-Whitney test; KW: Kruskal-Wallis test.  
a Clinical judgment on dementia (yes/no). 
* Numbers that do not sum 584 are due to missing data 
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Table4. Linear regression models for Zarit as dependent variable. 
 
 Total sample* PD-No dementia  
(n=477) 
PD-Dementia 
(n=93) 
 
Standardized 
beta p 
Standardized 
beta 
p Standardized 
beta 
p 
SEND-PD Mood/apathy 0.284 <0.001 0.281 <0.001 0.277 0.011 
CISI-PD Disability 0.213 <0.001 0.213 <0.001 -- -- 
SEND-PD Psychosis 0.184 <0.001 0.145 0.002 0.315 0.004 
Disease duration 0.112 0.003 0.132 0.002 -- -- 
R Squared 0.38  0.30  0.25  
Independent variables in all models: disease duration, CISI-PD Disability item, and the SEND-
PD subscales (mood/apathy, psychosis and impulse control disorders). Empty cells mean non-
significant variables. 
* Also includes the variable “clinical judgment on dementia”, which was not significant. 
 
 
